Oruka Therapeutics to Present at Multiple November Investor Conferences
Oruka Therapeutics to Present at Multiple November Investor Conferences
A webcast and replay of Oruka's presentation will be available on the Oruka investor events website at .MENLO PARK, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced presentations at the following upcoming investor conferences:
加州門洛帕克，2024年11月4日(GLOBE NEWSWIRE)——Oruka Therapeutics, Inc.（「Oruka」）（納斯達克：ORKA），一家開發旨在爲慢性皮膚病如銀屑病等設定新標準的新型生物製品的生物技術公司，今日宣佈將在即將舉行的投資者會議上進行演講：
Stifel 2024 Healthcare Conference
Date: Monday, November 18th, 2024
Time: 2:25PM ET
2024年史蒂夫爾醫療保健大會
日期：2024年11月18日星期一
時間：下午2:25（東部時間）
Jefferies London Healthcare Conference
Date: Wednesday, November 20th, 2024
Time: 2:00PM GMT
傑富瑞倫敦醫療保健大會
日期：2024年11月20日星期三
時間：下午2點 GMT
A webcast and replay of Oruka's presentation will be available on the Oruka investor events website at .
Oruka的在線研討會和演講回放將在Oruka投資者活動網站上提供 .
About Oruka Therapeutics
全新的生物製品研發公司Oruka Therapeutics正致力於開發針對慢性皮膚病的全新生物製品，以實現全面治癒患有牛皮癬等慢性皮膚病患者的使命。Oruka正在推進由Paragon Therapeutics工程團隊設計的一系列專有的抗體，這些抗體是可能最好的類似產品，並針對牛皮癬和其他皮膚炎症疾病的核心機制。欲了解更多信息，請訪問www.orukatx.com。
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka's mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit and follow Oruka on LinkedIn.
Oruka生物製品正在開發新型生物製品，旨在爲慢性皮膚疾病治療設定新標準。Oruka的使命是爲患有斑塊性銀屑病等慢性皮膚疾病的患者提供儘可能多的病症解除自由，通過每年一到兩次的不經常用藥實現高達病情完全清除的高比例。Oruka正在推進由Paragon Therapeutics設計的一系列潛在最佳抗體組合，針對斑塊性銀屑病和其他皮膚病和炎症性疾病的核心機制。欲了解更多信息，請訪問 並關注LinkedIn上的Oruka。
Investor Contact:
Alan Lada
(650)-606-7911
alan.lada@orukatx.com
投資者聯繫：
Alan Lada
(650)-606-7911
alan.lada@orukatx.com
譯文內容由第三人軟體翻譯。
